Interferon-α - Revision history

Neil.m.young: Text replacement - "α2" to "α₂"

2017-08-08T23:31:49Z

Text replacement - "α2" to "α<sub>2</sub>"

← Older revision		Revision as of 23:31, 8 August 2017
Line 6:		Line 6:

	==Adult Dosing==		==Adult Dosing==
	*Variable depending on indication and formulation (interferon-~~α2A~~, -~~α2B~~, -αn3, -alfacon, peginterferon α-2a, peginterferon α-2b)		*Variable depending on indication and formulation (interferon-α<sub>2</sub>A, -α<sub>2</sub>B, -αn3, -alfacon, peginterferon α-2a, peginterferon α-2b)
	*Used to treat:		*Used to treat:
	**Chronic hepatitis B, chronic hepatitis C		**Chronic hepatitis B, chronic hepatitis C
Line 17:		Line 17:

	==Pediatric Dosing==		==Pediatric Dosing==
	*Variable depending on indication and formulation (interferon-~~α2A~~, -~~α2B~~, -αn1, -αn3, -alfacon)		*Variable depending on indication and formulation (interferon-α<sub>2</sub>A, -α<sub>2</sub>B, -αn1, -αn3, -alfacon)
	*Used to treat:		*Used to treat:
	**chronic myelogenous leukemia (Philadelphia chromosome positive)		**chronic myelogenous leukemia (Philadelphia chromosome positive)
Line 26:		Line 26:
	*[[Drug pregnancy categories\|Pregnancy Rating]]: C. When used with ribavirin, may lead to fetal defects or fetal death		*[[Drug pregnancy categories\|Pregnancy Rating]]: C. When used with ribavirin, may lead to fetal defects or fetal death
	*Lactation risk: Infant risk cannot be ruled out		*Lactation risk: Infant risk cannot be ruled out
	*Renal dosing: IFN-~~α2B~~ and pegylated IFN-~~α2B~~ contraindicated if CrCl <50		*Renal dosing: IFN-α<sub>2</sub>B and pegylated IFN-α<sub>2</sub>B contraindicated if CrCl <50
	*Hepatic dosing: contraindicated in decompensated liver disease		*Hepatic dosing: contraindicated in decompensated liver disease

Line 75:		Line 75:
	==Pharmacology==		==Pharmacology==
	*Half-life: 2 to 160h		*Half-life: 2 to 160h
	*Metabolism: Hepatic, renal (IFN-~~α2A~~)		*Metabolism: Hepatic, renal (IFN-α<sub>2</sub>A)
	*Excretion: Renal		*Excretion: Renal

Mholtz: Text replacement - "* " to "*"

2017-07-11T20:29:12Z

Text replacement - "* " to "*"

← Older revision		Revision as of 20:29, 11 July 2017
Line 11:		Line 11:
	**Polycythemia vera, essential thrombocytopenia		**Polycythemia vera, essential thrombocytopenia
	**Condyloma acuminatum (refractory/recurrent)		**Condyloma acuminatum (refractory/recurrent)
	** Kaposi's sarcoma, Malignant melanoma (adjunct)		**Kaposi's sarcoma, Malignant melanoma (adjunct)
	**Carcinoid tumor		**Carcinoid tumor
	**Multiple myeloma, hairy cell leukemia, follicular lymphoma, chronic myelogenous leukemia (Philadelphia chromosome positive)		**Multiple myeloma, hairy cell leukemia, follicular lymphoma, chronic myelogenous leukemia (Philadelphia chromosome positive)
Line 21:		Line 21:
	**chronic myelogenous leukemia (Philadelphia chromosome positive)		**chronic myelogenous leukemia (Philadelphia chromosome positive)
	**Chronic hepatitis B, chronic hepatitis C		**Chronic hepatitis B, chronic hepatitis C
	** Papillomatosis (adjunct)		**Papillomatosis (adjunct)

	==Special Populations==		==Special Populations==

ClaireLewis: Created page with "==Administration== Type: Antiviral, antineoplastic Dosage Forms: Routes of Administration: Injection Common Trade Names: ==Adult Dosing== *Variable depending on ind..."

2017-02-25T23:57:37Z

Created page with "==Administration== *Type: Antiviral, antineoplastic *Dosage Forms: *Routes of Administration: Injection *Common Trade Names: ==Adult Dosing== *Variable depending on ind..."

New page

==Administration==
*Type: [[Antiviral]], antineoplastic
*Dosage Forms:
*Routes of Administration: Injection
*Common Trade Names:

==Adult Dosing==
*Variable depending on indication and formulation (interferon-α2A, -α2B, -αn3, -alfacon, peginterferon α-2a, peginterferon α-2b)
*Used to treat:
**Chronic hepatitis B, chronic hepatitis C
**Polycythemia vera, essential thrombocytopenia
**Condyloma acuminatum (refractory/recurrent)
** Kaposi's sarcoma, Malignant melanoma (adjunct)
**Carcinoid tumor
**Multiple myeloma, hairy cell leukemia, follicular lymphoma, chronic myelogenous leukemia (Philadelphia chromosome positive)
**Metastatic renal cell carcinoma

==Pediatric Dosing==
*Variable depending on indication and formulation (interferon-α2A, -α2B, -αn1, -αn3, -alfacon)
*Used to treat:
**chronic myelogenous leukemia (Philadelphia chromosome positive)
**Chronic hepatitis B, chronic hepatitis C
** Papillomatosis (adjunct)

==Special Populations==
*[[Drug pregnancy categories|Pregnancy Rating]]: C. When used with ribavirin, may lead to fetal defects or fetal death
*Lactation risk: Infant risk cannot be ruled out
*Renal dosing: IFN-α2B and pegylated IFN-α2B contraindicated if CrCl <50
*Hepatic dosing: contraindicated in decompensated liver disease

==Contraindications==
*Allergy to class/drug or inactive ingredients: may contain benzyl peroxide, bovine/ovine Ig, mouse IgG, polymyxin B, neomycin, egg protein
*Autoimmune hepatitis
*Decompensated liver disease
*Hemoglobinopathies (e.g. thalassemia major, sickle cell) when used with ribavirin
*Pregnancy or men with pregnant female partners (in combination with ribavirin)

==Adverse Reactions==
===Serious===
*Dysrhythmia, hypotension, cardiomyopathy, MI
*Raynaud's disease, vasculitis
*Diabetes, hypertriglyceridemia, decreased body growth
*GI bleed, ischemic colitis
*Pancreatitis
*Anemia, aplastic anemia, thrombocytopenia, lymphocytopenia, neutropenia
*TTP
*Hepatotoxicity
*Autoimmune disease, lupus
*Rhabdomyolysis, myositis
*Stroke, cerebral hemorrhage, coma, encephalopathy
*Seizure
*Visual loss, optic neuritis, retinal hemorrhage, retinal artery/vein thrombosis
*Suicidal ideation/behavior, depression, psychotic disorder, agressive behavior
*Obliterative bronchiolitis, pneumonitis, pneumothorax, PE, pulmonary hypertension, sarcoidosis
*Erythroderma, Stevens-Johnson syndrome
*Infection

===Common===
*Alopecia
*Dermatitis, pruritus, dry skin, injection site reaction
*Weight loss
*Nausea/vomiting, abdominal pain, diarrhea, anorexia,
*Neutropenia
*Elevated AST/SGOT
*Thyroid dysfunction
*Musculoskeletal pain
*Asthenia, dizziness, fatigue, paresthesias
*Headache
*Depression, anxiety
*Cough dyspnea
*Edema
*Fever, influenza-like illness

==Pharmacology==
*Half-life: 2 to 160h
*Metabolism: Hepatic, renal (IFN-α2A)
*Excretion: Renal

==Mechanism of Action==
*Interferons induce various cell activities, such as antiviral activity, suppression of cell proliferation, augmentation of macrophage activity and other immunomodulating effects.

==Comments==

==See Also==
*[[Antiviral]]
*[[Hepatitis B]], [[Hepatitis C]]

==References==
<references/>

[[Category:Pharmacology]]

Interferon-α - Revision history

Neil.m.young: Text replacement - "α2" to "α2"

Mholtz: Text replacement - "* " to "*"

ClaireLewis: Created page with "==Administration== *Type: Antiviral, antineoplastic *Dosage Forms: *Routes of Administration: Injection *Common Trade Names: ==Adult Dosing== *Variable depending on ind..."

Neil.m.young: Text replacement - "α2" to "α₂"

ClaireLewis: Created page with "==Administration== Type: Antiviral, antineoplastic Dosage Forms: Routes of Administration: Injection Common Trade Names: ==Adult Dosing== *Variable depending on ind..."